A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business Esperion is a commercial stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. We have developed and are commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease, or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. Through commercial execution, international partnerships and collaborations, and advancement of our pre-clinical pipeline, we continue to evolve into a leading global biopharmaceutical company.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | % of Total |
|---|---|---|---|---|---|---|
Collaboration Revenue | $38M | $20M | $38M | $217M | $244M | 38% |
Product | $40M | $56M | $78M | $116M | $160M | 25% |
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received | — | $18M | $37M | $205M | $149M | 23% |
Otsuka Pharmaceutical Co Ltd | — | $1M | $0M | $11M | $91M | 14% |
Royalty Revenue From DSE And Sale Of Bulk Tablets | $10M | $18M | $37M | — | — | — |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 403M | 403M | 332M | 116M | - | - |
| Net Income | -23M | -23M | -52M | -209M | -234M | -269M |
| EPS | $-0.11 | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 |
| Free Cash Flow | -13M | -13M | -24M | -135M | -175M | -264M |
| ROIC | 10.2% | 14.9% | 15.8% | -75.6% | -72.4% | -46.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.51 | -0.66 | -0.58 | -0.81 | -1.32 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 60M | 60M | 54M | -156M | -180M | -227M |
| Operating Margin | 15.0% | 15.0% | 16.4% | -133.7% | - | - |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 206M | 206M | 185M | 103M | 185M | 77M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 148M | 228M | N/A | N/A | 116M | 332M | 403M | 403M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 176M | 147M | 106M | 119M | 86M | 46M | 48M | 48M |
| SG&A | 66M | 200M | 185M | 109M | 143M | 163M | 166M | 166M |
| EBIT | -93M | -121M | -227M | -180M | -156M | 54M | 60M | 60M |
| Op. Margin | -62.8% | -53.3% | N/A | N/A | -133.7% | 16.4% | 15.0% | 15.0% |
| Net Income | -97M | -144M | -269M | -234M | -209M | -52M | -23M | -23M |
| Net Margin | -65.5% | -63.1% | N/A | N/A | -179.9% | -15.6% | -5.6% | -5.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -34.3% | -172.5% | -46.9% | -72.4% | -75.6% | 15.8% | 14.9% | 10.2% |
| ROE | -487.0% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -45.3% | -40.6% | -70.5% | -94.2% | -101.7% | -15.0% | -5.6% | -4.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | -70M | -85M | -264M | -175M | -135M | -24M | -13M | -13M |
| Free Cash Flow | -71M | -86M | -264M | -175M | -135M | -24M | -13M | -13M |
| Owner Earnings | -97M | -114M | -289M | -191M | -148M | -36M | -23M | -23M |
| CapEx | 953K | 869K | 0 | 0 | 0 | 317K | 0 | 0 |
| Maint. CapEx | 319K | 547K | 612K | 500K | 164K | 63K | 105K | 105K |
| Growth CapEx | 634K | 322K | N/A | N/A | N/A | 254K | N/A | 0 |
| D&A | 319K | 547K | 612K | 500K | 164K | 63K | 105K | 105K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 55M | 0 | 55M | 55M | 55M | 0 | 0 |
| Buyback Yield | N/A | 7.2% | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 26M | 28M | 24M | 15M | 12M | 12M | 9.9M | 9.9M |
| Debt Repayment | 1.0M | 8.4M | 440K | 0 | 0 | 210M | 55M | 55M |
| Balance Sheet | ||||||||
| Net Debt | -199M | -401M | 863K | 94M | 102M | -34M | -181M | -13M |
| Cash & Equiv. | 166M | 305M | 209M | 125M | 82M | 145M | 168M | 168M |
| Long-Term Debt | 0 | 179M | 258M | 260M | 262M | 141M | 152M | 152M |
| Debt/Equity | 0.08 | -1.93 | -1.32 | -0.81 | -0.58 | -0.66 | -0.51 | 0.00 |
| Interest Coverage | -11.5 | -5.4 | -4.9 | -3.2 | -2.6 | 0.9 | 0.7 | 0.7 |
| Equity | 20M | -96M | -197M | -324M | -455M | -389M | -302M | -302M |
| Total Assets | 214M | 353M | 382M | 248M | 206M | 344M | 466M | 466M |
| Total Liabilities | 194M | 449M | 579M | 572M | 661M | 733M | 768M | 768M |
| Intangibles | 56K | 56K | 56K | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -695M | -839M | -1.1B | -1.3B | -1.5B | -1.6B | -1.6B | -1.6B |
| Working Capital | 146M | 252M | 256M | 154M | 45M | 92M | 162M | 162M |
| Current Assets | 212M | 346M | 329M | 247M | 201M | 338M | 463M | 463M |
| Current Liabilities | 66M | 94M | 73M | 92M | 156M | 246M | 301M | 301M |
| Per Share Data | ||||||||
| EPS | -3.59 | -5.23 | -9.31 | -3.52 | -2.03 | -0.28 | -0.11 | -0.11 |
| Owner EPS | -3.57 | -1.82 | -3.77 | -1.03 | -1.43 | -0.19 | -0.11 | -0.11 |
| Book Value | 0.74 | -1.53 | -2.57 | -1.75 | -4.41 | -2.10 | -1.46 | -1.46 |
| Cash Flow/Share | -2.60 | -1.36 | -3.45 | -0.94 | -1.31 | -0.13 | -0.06 | -0.11 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 27.1M | 62.8M | 76.6M | 185.1M | 103.1M | 184.8M | 206.2M | 206.2M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -20.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | 7.7 | N/A | 7.4 |
| Price/Book | 80.8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | 8.0 | 5.0 | N/A | N/A | 2.1 | 1.3 | N/A | 1.1 |
| FCF Yield | -4.4% | -11.3% | -185.5% | -44.6% | -42.7% | -5.7% | N/A | -2.9% |
| Market Cap | 1.6B | 761M | 142M | 392M | 317M | 421M | 0 | 458M |
| Avg. Price | 43.96 | 41.26 | 19.19 | 5.99 | 2.36 | 2.29 | 0.00 | 2.22 |
| Year-End Price | 59.56 | 27.72 | 4.92 | 5.90 | 3.08 | 2.28 | 0.00 | 2.22 |
Esperion Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Esperion Therapeutics, Inc. (ESPR) has a 5-year average return on invested capital (ROIC) of -32.8%. This is below average and may indicate limited pricing power.
Esperion Therapeutics, Inc. (ESPR) has a market capitalization of $458M. It is classified as a small-cap stock.
Esperion Therapeutics, Inc. (ESPR) does not currently pay a regular dividend.
Esperion Therapeutics, Inc. (ESPR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Esperion Therapeutics, Inc. (ESPR) reported annual revenue of $403 million in its most recent fiscal year, based on SEC EDGAR filings.
Esperion Therapeutics, Inc. (ESPR) has a net profit margin of -5.6%. The company is currently unprofitable.
Esperion Therapeutics, Inc. (ESPR) generated $-13 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Esperion Therapeutics, Inc. (ESPR) reported earnings per share (EPS) of $-0.11 in its most recent fiscal year.
The Ledger Terminal provides 7 years of financial data for Esperion Therapeutics, Inc. (ESPR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Esperion Therapeutics, Inc. (ESPR) has a book value per share of $-1.46, based on its most recent annual SEC filing.